TESARO, Inc. (TSRO) Given Consensus Recommendation of “Buy” by Brokerages
Shares of TESARO, Inc. (NASDAQ:TSRO) have received a consensus rating of “Buy” from the twenty-seven ratings firms that are presently covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, ten have issued a hold recommendation, fourteen have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month price objective among brokers that have issued a report on the stock in the last year is $174.32.
TSRO has been the subject of several research reports. FBR & Co lowered their price objective on shares of TESARO from $202.00 to $200.00 and set a “mkt perform” rating for the company in a research note on Wednesday, May 10th. Cowen and Company reissued a “hold” rating and set a $145.00 price objective on shares of TESARO in a research note on Thursday, May 11th. Jefferies Group LLC reissued a “hold” rating on shares of TESARO in a research note on Wednesday, May 10th. Cann reissued an “outperform” rating on shares of TESARO in a research note on Wednesday, May 24th. Finally, Oppenheimer Holdings, Inc. initiated coverage on shares of TESARO in a research note on Thursday, May 25th. They set an “outperform” rating and a $183.00 price objective for the company.
In other TESARO news, VP Edward C. English sold 8,500 shares of the company’s stock in a transaction dated Tuesday, June 6th. The shares were sold at an average price of $138.65, for a total value of $1,178,525.00. Following the completion of the transaction, the vice president now directly owns 5,396 shares of the company’s stock, valued at approximately $748,155.40. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Corporate insiders own 34.60% of the company’s stock.
A number of institutional investors have recently bought and sold shares of the stock. BlackRock Inc. boosted its position in TESARO by 4,504.8% in the first quarter. BlackRock Inc. now owns 3,409,657 shares of the biopharmaceutical company’s stock worth $524,643,000 after buying an additional 3,335,611 shares during the last quarter. Janus Henderson Group PLC purchased a new position in TESARO during the second quarter worth $100,301,000. PointState Capital LP purchased a new position in TESARO during the second quarter worth $85,971,000. TIAA CREF Investment Management LLC boosted its position in TESARO by 167.9% in the first quarter. TIAA CREF Investment Management LLC now owns 367,519 shares of the biopharmaceutical company’s stock worth $56,550,000 after buying an additional 230,353 shares during the last quarter. Finally, Pioneer Investment Management Inc. boosted its position in TESARO by 195.6% in the second quarter. Pioneer Investment Management Inc. now owns 317,753 shares of the biopharmaceutical company’s stock worth $44,441,000 after buying an additional 210,273 shares during the last quarter.
Shares of TESARO (NASDAQ:TSRO) traded up 1.89% during midday trading on Wednesday, hitting $126.58. The company had a trading volume of 770,054 shares. TESARO has a 12 month low of $83.26 and a 12 month high of $192.94. The company has a 50-day moving average of $123.96 and a 200-day moving average of $146.46. The company’s market capitalization is $6.86 billion.
TESARO (NASDAQ:TSRO) last announced its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($2.82) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($2.52) by $0.30. TESARO had a negative net margin of 1,301.19% and a negative return on equity of 104.00%. The company had revenue of $29.50 million for the quarter, compared to analysts’ expectations of $18.61 million. During the same period in the prior year, the firm earned ($1.28) earnings per share. The firm’s quarterly revenue was down 17.6% on a year-over-year basis. Analysts predict that TESARO will post ($8.67) earnings per share for the current year.
TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.
Receive News & Ratings for TESARO Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.